7T Amygdala and Citalopram Study
The Effects of Citalopram on the Brain's Response to Faces
University of Oxford
50 participants
Feb 13, 2025
INTERVENTIONAL
Conditions
Summary
The goal of this study is to investigate how a common antidepressant citalopram (which increases the levels of the chemical messenger serotonin), affects how a key area of the brain involved in depression (the amygdala) responds to emotional information. Healthy participants will undergo medical and psychiatric health screening, after which they will be assigned to receive either a single dose of citalopram (20mg) or placebo, and undergo brain scanning (7T fMRI) whilst viewing emotional faces. Since the scan uses high field strength, the investigators will be able to see effects of citalopram on different subfields within the amygdala which will help to understand how citalopram might be working.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Participants will receive a single dose (20mg) citalopram. Tablets encapsulated to aid blinding. To take per oral once.
Participants will receive a single dose of placebo (sucrose). Tablets encapsulated to aid blinding. To take per oral once
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06412315